The presentation by Prof Lemmens was a unique opportunity to learn about the clinical experience with stroke directly from an unrivalled expert. He made it very clear that intracerebral hemorrhage presents a large unmet medical need that could be addressed by BIOX-101 if further studies confirm the signals we have seen in our Phase 2a trial.